Email address for general EMBRACE related enquiries and for centres to order questionnaires and blood kit packs:
embrace@medschl.cam.ac.uk

Recent Publications:

Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.
Li, S et al.
Journal of Clinical Oncology; 25 Jan 2022; DOI: 10.1200/JCO.21.02112

Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
Daniel R Barnes, et al.
J Natl Cancer Inst. 2022 Jan 11;114(1):109-122. doi: 10.1093/jnci/djab147.

The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.
Inge M M Lakeman # et al.
Genet Med. 2021 Sep;23(9):1726-1737. doi: 10.1038/s41436-021-01198-7. Epub 2021 Jun 10.

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.
Juliette Coignard, et al.
Nat Commun. 2021 Feb 17;12(1):1078. doi: 10.1038/s41467-020-20496-3.

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study
Lieske H Schrijver, et al.
Am J Obstet Gynecol. 2021 Jul;225(1):51.e1-51.e17. doi: 10.1016/j.ajog.2021.01.014. Epub 2021 Jan 22.

Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study
Tommy Nyberg, et al
Eur Urol. 2020 Jan;77(1):24-35. doi: 10.1016/j.eururo.2019.08.025. Epub 2019 Sep 6.

Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study
Frank Qian, et al.
J Natl Cancer Inst. 2019 Apr 1;111(4):350-364. doi: 10.1093/jnci/djy132.

Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study
Lieske H Schrijver, et al.
JNCI Cancer Spectr. 2018 Jun 28;2(2):pky023. doi: 10.1093/jncics/pky023. eCollection 2018 Apr.

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Karoline B Kuchenbaecker et al.
JAMA. 2017 Jun 20;317(23):2402-2416. doi: 10.1001/jama.2017.7112.

Candido-dos-Reis FJ et al. (2015) Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.
Clin Cancer Res.

Castro E et al. (2015) Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.
Eur Urol.

Pooley KA, McGuffog L, Barrowdale D, et al. (2014) Lymphocyte telomere length is longer in BRCA1 and BRCA2 mutation carriers but does not affect subsequent cancer risk.
Cancer Epidemiology, Biomarkers & Prevention

Philips KA et al. (2013) Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
J Clin Oncol.

Mavaddat N, Peock S, Frost D, et al. (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
J Natl Cancer Inst.

Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study
Antonis C Antoniou et al.
Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):601-10.

EMBRACE data are used in all publications from the CIMBA consortium.